

ASX RELEASE

19th October 2023

AMPLIA RECEIVES R&D TAX REBATE TOTALLING \$ 2.4 MILLION

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received a Research and Development (R&D) Tax Incentive refund of \$2,408,458 for the 2022/2023 financial year. The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, AMP945 and AMP886.

These R&D activities primarily related to the Company’s Phase 1b/2a clinical trial of AMP945 in advanced pancreatic cancer patients which opened in April 2022 with dosing of the first patient occurring in August 2022.

Following receipt of the funds, the Company will fully repay the Victorian Government R&D Cash Flow Initiative Loan of \$2,100,000. The Company undertook the loan in two tranches in December 2021 and February 2022. The net funds will contribute to the further progression of the Company’s Phase 1b/2a clinical trial of AMP945 and other R&D activities.

The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).